What Has Been the Growth of the Bronchodilators Market So Far?
The bronchodilators market has seen considerable growth due to a variety of factors.
• The market for bronchodilators has demonstrated impressive expansion over the past few years. It is projected to escalate from a valuation of $32.93 billion in 2024 to $35.66 billion in 2025, with a compound annual growth rate (CAGR) of 8.3%.
Several factors have contributed to the historic period of growth, including an increasing elderly population, a surge in asthma cases, enhanced funding from governmental bodies, an uptick in the ageing populace, and a rise in global air pollution.
How Will the Bronchodilators Market?
The bronchodilators market is expected to maintain its strong growth trajectory in upcoming years.
• Projected robust expansion is on the cards for the bronchodilators market, with its size expected to increase to $45.97 billion in 2029, growing at a compound annual growth rate (CAGR) of 6.6%.
The expected growth in the forthcoming years can be credited to factors like an increased occurrence of COPD, enhanced consciousness about therapies for lung diseases, and increased research and development. Additional contributing factors include rising pulmonary disorder cases, growing disposable income, and an uptick in smoking rates. Noteworthy trends shaping this forecast period include advanced clinical research, innovative strategic approaches, technological growth, an increased incidence of lung diseases such as COPD and asthma, new product introductions, and a rise in acute respiratory infection patients.
Which Factors Are Boosting Growth In The Bronchodilators Market?
With an escalating presence of chronic obstructive pulmonary disease (COPD) worldwide, the bronchodilator market is anticipated to experience significant expansion. COPD, a gradually worsening lung condition involving chronic inflammation and airway hindrance, often necessitates the use of bronchodilators to loosen the airway muscles, thereby enhancing breathing ease. For example, a March 2023 report by the Scottish Public Health Observatory, steered by Public Health Scotland, indicated an upsurge in COPD rates following the easing of COVID-19 impacts. Male rates of COPD surged from 83.2 to 97.6 cases per 100,000, and female rates experienced a similar increase from 72.6 to 97.3. Thus, the growing incidence of chronic obstructive pulmonary disease (COPD) is fueling the advancements in the bronchodilator market.
What Key Areas Define The Segmentation Of The Global Bronchodilators Market?
The bronchodilators market covered in this report is segmented –
1) By Type: Beta-Adrenergic Bronchodilators, Anticholinergic Bronchodilators, Xanthine Derivatives, Other Types
2) By Route of Administration: Oral, Nasal (Inhalation), Injectable
3) By Indication: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Allergic Reactions, Breathing Problem, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Other End Users
Subsegments:
1) By Beta-Adrenergic Bronchodilators: Short-Acting Beta Agonists (SABAs), Long-Acting Beta Agonists (LABAs)
2) By Anticholinergic Bronchodilators: Short-Acting Anticholinergics, Long-Acting Anticholinergics
3) By Xanthine Derivatives: Theophylline, Aminophylline
4) By Other Types: Leukotriene Receptor Antagonists, Combination Therapies
Pre-Book The Bronchodilators Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Reshaping The Future Of The Bronchodilators Market?
Major firms in the bronchodilator market are introducing fresh and innovative products, such as fixed-dose triple-drug combinations, to better accommodate their patients. Triple-drug combinations are medications that contain three active components in one formulation, with a set dose of each ingredient. Lupin, a pharmaceutical company based in India, for example, launched DIFIZMA in January 2023. This is a fixed-dose triple-drug bronchodilator comprised of indacaterol, glycopyrronium, and mometasone for the treatment of asthma. DIFIZMA is administered as a dry powder inhalation. The Drug Controller General of India (DCGI) has solely approved DIFIZMA as a fixed dose combination for inadequately controlled asthma; this helps increase lung function, gives better symptom control, and lowers exacerbations.
Who Are the Key Players In The Bronchodilators Market?
Major companies operating in the bronchodilators market report are:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• Novartis AG
• Thermo Fisher Scientific
• Abbott Laboratories
• Sanofi S.A.
• GlaxoSmithKline plc
• Siemens Healthcare GmbH
• Merck & Co. Inc.
• AstraZeneca plc
• Teva Pharmaceuticals Industries Ltd.
• Mylan N.V.
• Quest Diagnostics Incorporated.
• Boehringer Ingelheim International GmbH
• Aurobindo Pharma Limited
• Bio-Rad Laboratories Inc.
• Cipla Limited
• Hikma Pharmaceutical plc
• Amneal Pharmaceuticals LLC
• Glenmark Pharmaceuticals Limited
• Vectura Group Limited
• Foundation Medicine Inc.
• Sun Pharmaceutical Industries Ltd.
• Amgen Inc.
• Kissei Pharmaceutical Co.Ltd.
• Mitsubishi Tanabe Pharma
• Theron Pharmaceuticals
• Viatris Inc.
What Is The Most Dominant Region In The Bronchodilators Market?
North America was the largest region in the bronchodilators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchodilators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
